BACKGROUND Oral and gastrointestinal (GI) mucositis can affect up to 100% of patients
undergoing high‐dose chemotherapy and hematopoietic stem cell transplantation, 80% of …

Mucositis is a common and feared complication of anticancer therapy that can affect up to
90% of certain populations of patients with cancer. Even seemingly uncomplicated …

Oral and gastrointestinal mucositis due to cancer therapies such as high-dose
chemotherapy and/or radiation continues to be an important clinical problem. Fortunately …

Considerable progress in research and clinical application has been made since the
original guidelines for managing mucositis in cancer patients were published in 2004, and …

Oral mucositis (OM) has emerged as a common cause of dose delays and interruptions of
cancer therapies such as multicycle chemotherapy, myeloablative chemotherapy, and …

BACKGROUND A frequent complication of anticancer treatment, oral and gastrointestinal
(GI) mucositis, threatens the effectiveness of therapy because it leads to dose reductions …

OBJECTIVES: To present a clinical update of evidence that applies to the development of a
nursing plan of care for the prevention and treatment of oral mucositis related to cytotoxic …

Background Mucositis is a significant toxicity of cancer therapy with numerous systemic
sequelae. The goal of this systematic review was to update the Multinational Association of …

OBJECTIVES: To review current evidence that applies to the development of a nursing plan
of care for the prevention and treatment of oral mucositis related to cytotoxic therapy. DATA …

Purpose The purpose of this project was to evaluate research in basic oral care
interventions to update evidence-based practice guidelines for preventing and treating oral …